Pfizer advances clinical trials for 5- to 11-year-olds at lower doses
(NEW YORK) -- Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical company announced Tuesday.
Based on safety, efficacy and tolerability data from Pfizer's Phase 1 trial, the company will use 10 micrograms of each... Read More.
